Compounded GLP-1 is not categorically dangerous, but the bar for 'safe enough' is higher than most patients know

What compounded GLP-1 actually is

Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are prescription products with FDA-reviewed prescribing information covering dosing, administration and warnings [5][6]. A compounded version is made by a state-licensed pharmacy or an outsourcing facility instead of the manufacturer, and FDA is explicit that such a product is not FDA approved and has not been reviewed for safety, effectiveness or quality [1]. All current US GLP-1 products are prescription-only [5][9].

One line is absolute. Retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of any FDA-approved drug, and have not been found safe and effective for any condition [1]. FDA has warned telehealth companies for marketing them, ingredient distributors for selling them to compounders, and outsourcing facilities for repackaging them [1].

What federal law allows now

A compounded drug made by a pharmacy must be made for an individual patient based on a prescription. FDA limits when a compounded drug may be treated as a copy of an available approved drug, and a documented significant difference for an identified patient can matter [2]. FDA has said that, at this time, it does not intend to act against a compounder who fills four or fewer prescriptions of such a product in a calendar month [2].

For outsourcing facilities, FDA's April 2026 update says semaglutide and tirzepatide do not currently appear on the bulk substances list they may compound from [2]. On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that list, finding no clinical need for them; comments were due 2026-06-29 and the agency said it would consider them before making a final determination [3].

The documented problems are practical, not hypothetical

FDA has received adverse-event reports for compounded semaglutide and compounded tirzepatide, along with reports of dosing errors [2].

The concerns FDA lists are specific.

• Multi-dose vials. FDA recommends discarding a multi-dose vial 28 days after first use even if medication remains, because contamination risk rises after 28 days, and using a new sterile needle and syringe for every dose [1].
• Shipping. FDA has received complaints of compounded GLP-1 drugs arriving warm or with too little ice, and recommends not using any injectable GLP-1 that arrives warm or inadequately refrigerated [1].
• Screening and labels. Red flags include a seller that does not require screening and a prescription from a licensed doctor, labels with spelling errors or incorrect pharmacy addresses, a pharmacy name that may be fraudulent, packaging that is broken or lacks instructions for use, and medicine that looks different from what the patient received before [1].

What the approved labels warn about

The Wegovy label carries a boxed warning for thyroid C-cell tumors in rodents, with human relevance undetermined, and contraindicates the drug in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [5]. Labeled risks for the approved semaglutide products include acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or a sulfonylurea, severe gastrointestinal reactions, and pulmonary aspiration during general anesthesia or deep sedation [5].

Gastrointestinal effects are the common ones in the approved products and are worst during dose escalation. In the Wegovy weight-management trials at 2.4 mg versus placebo, nausea occurred in 44% versus 16%, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; 6.8% versus 3.2% stopped treatment because of adverse reactions [5].

What the trials measured

The efficacy and cardiovascular numbers people quote come from the approved products. STEP 1, a double-blind trial of 1,961 adults with obesity or overweight and no diabetes, found a mean weight change of -14.9% with semaglutide 2.4 mg weekly versus -2.4% with placebo at 68 weeks [4]. SURMOUNT-1, 2,539 adults, found -15.0%, -19.5% and -20.9% with tirzepatide 5, 10 and 15 mg versus -3.1% with placebo at 72 weeks [7]. SELECT, 17,604 adults with established cardiovascular disease and a BMI of 27 or higher but no diabetes, found cardiovascular death, heart attack or stroke in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo over a mean 39.8 months [8].

What FDA says to look for

FDA says compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and that patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy [1]. FDA's red-flag list covers the parts of the chain a patient can see, and FDA does not review a compounded drug before it is sold [1].